Pharma Mar Price To Sales vs. Price To Book

PHM Stock  EUR 78.10  0.55  0.71%   
Considering Pharma Mar's profitability and operating efficiency indicators, Pharma Mar SA may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Pharma Mar's ability to earn profits and add value for shareholders.
For Pharma Mar profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pharma Mar to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pharma Mar SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pharma Mar's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pharma Mar SA over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Please note, there is a significant difference between Pharma Mar's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharma Mar is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharma Mar's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pharma Mar SA Price To Book vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pharma Mar's current stock value. Our valuation model uses many indicators to compare Pharma Mar value to that of its competitors to determine the firm's financial worth.
Pharma Mar SA is considered to be number one stock in price to sales category among its peers. It also is considered to be number one stock in price to book category among its peers fabricating about  1.10  of Price To Book per Price To Sales. Comparative valuation analysis is a catch-all model that can be used if you cannot value Pharma Mar by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pharma Mar's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Pharma Price To Book vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Pharma Mar

P/S

 = 

MV Per Share

Revenue Per Share

 = 
5.17 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Pharma Mar

P/B

 = 

MV Per Share

BV Per Share

 = 
5.69 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Pharma Price To Book Comparison

Pharma Mar is currently under evaluation in price to book category among its peers.

Pharma Mar Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pharma Mar, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pharma Mar will eventually generate negative long term returns. The profitability progress is the general direction of Pharma Mar's change in net profit over the period of time. It can combine multiple indicators of Pharma Mar, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain. PHARMA MAR operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 599 people.

Pharma Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pharma Mar. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pharma Mar position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pharma Mar's important profitability drivers and their relationship over time.

Use Pharma Mar in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharma Mar position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharma Mar will appreciate offsetting losses from the drop in the long position's value.

Pharma Mar Pair Trading

Pharma Mar SA Pair Trading Analysis

The ability to find closely correlated positions to Pharma Mar could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharma Mar when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharma Mar - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharma Mar SA to buy it.
The correlation of Pharma Mar is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharma Mar moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharma Mar SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharma Mar can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Pharma Mar position

In addition to having Pharma Mar in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Iron Thematic Idea Now

Iron
Iron Theme
Companies involved in production of steel and iron. The Iron theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Iron Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Pharma Stock

To fully project Pharma Mar's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Pharma Mar SA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Pharma Mar's income statement, its balance sheet, and the statement of cash flows.
Potential Pharma Mar investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Pharma Mar investors may work on each financial statement separately, they are all related. The changes in Pharma Mar's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pharma Mar's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.